Trial data show hydroxychloroquine doesn't help hospitalized COVID patientsData released today from a randomized controlled trial evaluating the use of hydroxychloroquine in hospitalized COVID-19 patients show that the antimalaria drug was not associated with reductions in 28-day mortality but was linked with increased time in the hospital and an increased risk of progressing to mechanical ventilation or death.The interim results from the RECOVERY trial, which is evaluating several treatments in hospitalized COVID-19 patients in the United Kingdom, appeared today on the preprint server medRxiv and have not yet been peer reviewed.The results show that, among 1,561 patients randomly allocated hydroxychloroquine, 26.8% (418 patients) died